logo
ProjectEnded

The disruptive personalized machine-based genetic counseling platform

Sector: Residential • Location: Israel

Source: EU Funding & Tenders Portal

The promise of personalized medicine will soon materialize. However, this revolution will require genetic counsellors as key professional to facilitate patients´ informed decision-making. However, there are just 7,000 worldwide, insufficient to fulfil the ever-growing demand for these services (>40 million people tested in 2018). Likewise, health care organizations cannot implement genetic counsel

Status
Closed
Sector
Residential, Hospital, Commercial
Location
Israel
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about The disruptive personalized machine-based genetic counseling platform

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “The disruptive personalized machine-based genetic counseling platform” is an infrastructure initiative in the Residential sector, located in Israel. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

The promise of personalized medicine will soon materialize. However, this revolution will require genetic counsellors as key professional to facilitate patients´ informed decision-making. However, there are just 7,000 worldwide, insufficient to fulfil the ever-growing demand for these services (>40 million people tested in 2018). Likewise, health care organizations cannot implement genetic counselling (GC) as a tool to help patients understand, adapt and adjust to the medical and psychological consequences of their genetic tests results. Innovative automated solutions are needed to fully exploit the benefits from the upcoming genomic revolution to overcome, not just the shortage but also expensive, time consuming and not scalable current GC approach. At Igentify Ltd, an Israeli startup home to 32 highly-skilled individuals, we have created the first clinically-approved Igentify: A 4 module-based machine learning digital platform automating all stages from the GC process, starting from enrolment of the patient into the system, until the delivery of customized machine generated GC. Igentify incorporates 2 features simplifying and making scalable GC: (1) A set of algorithms analysing all genetic-related parameters (e.g. ethnicity, carrier frequency, medical history, lifestyle, etc.) to profile the individual as low or high-risk. (2) A revolutionary audio-visual asset generation algorithm that autonomously creates dynamic audio-visual content customized for patients, explaining all information in an educational way. We have commercial agreements with early adopters, including Northwell Health, Gene by Gene, Kaplan Medical Center or Meudehet, confirming Igentify´s business opportunity. We expect to gain a 4% market share within the global genetic testing market (€16.7 billion valuation by 2024, CAGR of 12.2%, period 2018-2024). This will translate into a revenue of € 104.06 M in 2026 (ROI of 7.04), while creating 150 jobs.

Location

Country

Israel

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Residential, Hospital, Commercial

Article published date

2026-02-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project